2017

Lanning BR, Vakoc CR. Single-minded CRISPR screening. Nat Biotechnol. 35(4):339-340 (2017).

Vakoc CR, Tuveson DA. Untangling the genetics from the epigenetics in pancreatic cancer metastasis. Nat Genet. Feb 24;49(3):323-324 (2017).

Ipsaro JJ, Shen C, Arai E, Xu Y, Kinney JB, Joshua-Tor L, Vakoc CR, Shi J. Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis. PLoS One. 12(2):e0172177 (2017).

Xu Y, Vakoc CR. Targeting Cancer Cells with BET Bromodomain Inhibitors. Cold Spring Harb Perspect Med. Feb 17 (2017).

Roe JS, Vakoc CR. The Essential Transcriptional Function of BRD4 in Acute Myeloid Leukemia. Cold Spring Harb Symp Quant Biol. Feb 7 (2017).

2016

Oran AR, Adams CM, Zhang XY, Gennaro VJ, Pfeiffer HK, Mellert HS, Seidel HE, Mascioli K, Kaplan J, Gaballa MR, Shen C, Rigoutsos I, King MP, Cotney JL, Arnold JJ, Sharma SD, Martinez-Outschoorn UE, Vakoc CR, Chodosh LA, Thompson JE, Bradner JE, Cameron CE, Shadel GS, Eischen CM, McMahon SB. Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. Oncotarget. (2016)

Huang YH, Vakoc CR. A Biomarker Harvest from One Thousand Cancer Cell Lines. Cell. 166(3):536-7 (2016).

Somerville TD, Vakoc CR. Modeling the Epigenetic Chain Reaction Downstream of DNMT3A(R882H). Cancer Cell. 30(1):9-10 (2016).

Hohmann AF, Martin LJ, Minder JL, Roe JS, Shi J, Steurer S, Bader G, McConnell D, Pearson M, Gerstberger T, Gottschamel T, Thompson D, Suzuki Y, Koegl M, Vakoc CR. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. Nat Chem Biol. 12(9):672-9 (2016).

Zhang Q, Zeng L, Shen C, Ju Y, Konuma T, Zhao C, Vakoc CR, Zhou MM. Structural Mechanism of Transcriptional Regulator NSD3 Recognition by the ET Domain of BRD4. Structure. 24(7):1201-8 (2016).

Tasdemir N, Banito A, Roe JS, Alonso-Curbelo D, Camiolo M, Tschaharganeh DF, Huang CH, Aksoy O, Bolden JE, Chen CC, Fennell M, Thapar V, Chicas A, Vakoc CR, Lowe SW. BRD4 Connects Enhancer Remodeling to Senescence Immune Surveillance. Cancer Discovery. 6(6):612-29 (2016).

Bhagwat AS, Roe JS, Mok BY, Hohmann AF, Shi J, Vakoc CR. BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements. Cell Reports. 15(3):519-30 (2016).

Martin LJ, Koegl M, Bader G, Cockcroft XL, Fedorov O, Fiegen D, Gerstberger T, Hofmann MH, Hohmann AF, Kessler D, Knapp S, Knesl P, Kornigg S, Müller S, Nar H, Rogers C, Rumpel K, Schaaf O, Steurer S, Tallant C, Vakoc CR, Zeeb M, Zoephel A, Pearson M, Boehmelt G, McConnell D. Structure-Based Design of an in Vivo Active Selective BRD9 Inhibitor. J Med Chem. 59(10):4462-75 (2016).

2015

Shen C, Ipsaro JJ, Shi J, Milazzo JP, Wang E, Roe JS, Suzuki Y, Pappin DJ, Joshua-Tor L, Vakoc CR. NSD3-Short Is an Adaptor Protein that Couples BRD4 to the CHD8 Chromatin Remodeler. Molecular Cell. 60(6):847-59 (2015).

Matthews GM, Mehdipour P, Cluse LA, Falkenberg KJ, Wang E, Roth M, Santoro F, Vidacs E, Stanley K, House CM, Rusche JR, Vakoc CR, Zuber J, Minucci S, Johnstone RW. Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood. 126(21):2392-403 (2015).

Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, Hoffmann T, Boryń ŁM, Axelsson E, Schweifer N, Tontsch-Grunt U, Dow LE, Gianni D, Pearson M, Valent P, Stark A, Kraut N, Vakoc CR, Zuber J. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 525(7570):543-7 (2015).

Bhagwat AS, Vakoc CR. Targeting Transcription Factors in Cancer. Trends in Cancer. 1(1): 53-65 (2015).

Roe JS, Mercan F, Rivera K, Pappin DJ,  Vakoc CR. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia. Molecular Cell. 58(6):1028-39 (2015).

Shi J, Wang E, Milazzo JP, Wang Z, Kinney JB, Vakoc CR. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nature Biotechnology. 33(6):661-7 (2015).

Wang E, Kawaoka S, Roe JS, Shi J, Hohmann AF, Xu Y, Bhagwat AS, Suzuki Y, Kinney JB, Vakoc CR. The transcriptional cofactor TRIM33 prevents apoptosis in B lymphoblastic leukemia by deactivating a single enhancer. eLife. 4:e06377 (2015).

Yu JR, Tai Y, Jin Y, Hammell MC, Wilkinson JE, Roe JS, Vakoc CR, Van Aelst L. TGF-β/Smad signaling through DOCK4 facilitates lung adenocarcinoma metastasis. Genes and Development. 29(3):250-61 (2015).

Shen C, Vakoc CR. Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention. Curr Opin Oncol. Jan;27(1):57-63 (2015).

2014

Xu Y, Vakoc CR. Brd4 is on the move during inflammation. Trends Cell Biol 24(11):615-6 (2014).

Mazurek A, Park Y, Miething C, Wilkinson JE, Gillis J, Lowe SW, Vakoc CR, Stillman B. Acquired dependence of acute myeloid leukemia on the DEAD-box RNA helicase DDX5. Cell Reports 7(6):1887-99 (2014).

Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Molecular Cell 54(5): 728-36 (2014).

Hohmann A, Vakoc CR. A rationale to target the SWI/SNF complex for cancer therapy. Trends in Genetics 30(8):356-63 (2014.)

Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, Blanco A, Chen S, Stützer A, Armache KJ, Simon MD, Xu C, Ali M, Murn J, Prisic S, Kutateladze TG, Vakoc CR, Min J, Kingston RE, Fischle W, Warren ST, Page DC, Shi Y. A chromatin-dependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell 157(4):869-81 (2014).

Chen C, Liu Y, Rappaport AR, Kitzing T, Schultz N, Zhao Z, Shroff AS, Dickins RA, Vakoc CR, Bradner JE, Stock W, LeBeau MM, Shannon KM, Kogan S, Zuber J, Lowe SW. MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25(5):652-65 (2014).

Vakoc CR, Garcia-Manero G, Look AT. Cancer therapy resistance: chasing epigenetics. Nature Medicine Apr;20(4):340-1 (2014).

Bhagwat AS, Vakoc CR. A new bump in the epigenetic landscape. Molecular Cell 53(6):857-8 (2014).

Roe JS, Vakoc CR. C/EBPα: critical at the origin of leukemic transformation. J Exp Med 211 1-4 (2014).

2013

Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, Minder JL, Mercan F, Wang E, Eckersley-Maslin MA, Campbell AE, Kawaoka S, Shareef S, Zhu Z, Kendall J, Muhar M, Haslinger C, Yu M, Roeder RG, Wigler MH, Blobel GA, Zuber J, Spector DL, Young RA, Vakoc CR. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes and Development 27, 2648-62 (2013)

Roe JS, Vakoc CR. Oncogene interference through targeting of chromatin regulators. Cell Cycle 12, 1475-6 (2013)

Shi J*, Wang E*, Zuber J, Rappaport A, Taylor M, Johns C, Lowe SW, Vakoc CR. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9; Nras (G12D) acute myeloid leukemia. Oncogene 32, 930-938 (2013).

Wang E*, Kawaoka S*, Yu M, Shi J, Ni T, Yang W, Shu J, Roeder RG, Vakoc CR. Histone H2B ubiquitin ligase RNF20 is required for MLL-rearranged leukemia. Proc Natl Acad Sci USA. 110, 3901-3906 (2013).

Lovén J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-34 (2013).

King B, Trimarchi T, Reavie L, Xu L, Mullenders J, Ntziachristos P, Aranda-Orgilles B, Perez-Garcia A, Shi J, Vakoc C, Sandy P, Shen SS, Ferrando A, Aifantis I. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell. 153(7):1552-66 (2013).

2012

Ernst P, Vakoc CR. WRAD: enabler of the SET1-family of H3K4 methyltransferases. Brief Funct Genomics 11, 217-226 (2012).

Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Mullauer L, Vakoc CR, Sperr WR, Horny HP, Bradner JE, Zuber J, Valent P. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem-and progenitor cells in acute myeloid leukemia AML. Oncotarget 3, 1588-1599 (2012).

2011

Zuber J*, Shi J*, Wang E, Rappaport AR, HerrmannH,SisonEA, Magoon D, Qi J, Blatt K, WunderlichM, TaylorMJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P,  Bradner JE, Lowe SW, Vakoc CR. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukemia. Nature 478, 524-528 (2011).

Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, Shi J, Weissmueller S, TaylorMJ, Weissenboeck M, Graeber TG, Kogan SC, Vakoc CR, Lowe SW. An integrated approach to dissecting oncogene addiction implicates a Myb coordinated self-renewal program as essential for leukemia maintenance. Genes and Development 25, 1628-40 (2011).

Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell 146, 904-17 (2011).

2010

Speck NA, Vakoc CR. PAF is in the cabal of MLL1-interacting proteins that promote leukemia. Cancer Cell 17, 531-532 (2010).

2009

Blobel GA, Kadauke S, Wang E, Lau AW, Zuber J, Chou MM, Vakoc CR. A Reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit. Molecular Cell 36, 970-983 (2009).

Tripic T, Deng W, Cheng Y, Zhang Y, Vakoc CR, Gregory GD, Hardison RC, Blobel GA. SCL and associated proteins distinguish active from repressive GATA transcription factor complexes. Blood 113, 2191-201 (2009).

Vakoc CR, Wen YW, Johnstone CN, Rustgi AK, Gibbs RA, Blobel GA. Low frequency of MLL3 mutations in colorectal carcinoma. Cancer Genetics and Cytogenetics. 189, 140-1 (2009).

Chou ST, Khandros E, Bailey LC, Nichols KE, Vakoc CR, Yao Y, Huang Z, Crispino JD, Hardison RC, Blobel GA, Weiss MJ. Graded Repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood 114, 983-94 (2009).

2008

Jing H, Vakoc CR, Mandat S, Wang H,  Zheng X, and Blobel GA. Exchange of GATA Factors Mediates Transitions in Looped Chromatin Organization at a Developmentally Regulated Gene Locus. Molecular Cell 29, 232-242 (2008).

Steger DJ, Lefterova MI, Stonestrom AJ, Schupp M, Zhuo D, Kim J, Chen J, Lazar MA, Blobel GA, and Vakoc CR. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Molecular and Cellular Biology 28, 2825-39 (2008).

2004-2007

Gregory GD, Vakoc CR, Rozovskaia T, Zheng X, Patel S, Nakamura T, Canaani E, and Blobel GA. The ASH1L histone methyltransferase occupies the transcribed region of active mammalian genes. Molecular and Cellular Biology 27, 8466-8479 (2007).

Yao Zeng P, Vakoc CR, Blobel GA, Berger SL. In vivo dual cross-linking for identification of indirect DNA-associated proteins by chromatin immunoprecipitation. Biotechniques 41, 694-698 (2006).

Vakoc CR, Sachdeva MM, Wang H, Blobel GA. A profile of histone lysine methylation across transcribed mammalian chromatin. Molecular and Cellular Biology 26, 9185-9195 (2006).

Lamonica J*, Vakoc CR*, Blobel GA. Acetylation of GATA-1 is required for chromatin occupancy. Blood 108, 3736-3738 (2006). * Equal Contribution

Vakoc CR, Mandat SA, Olenchock BA, Blobel GA. Histone H3 lysine 9 methylation and HP1γ are associated with transcription elongation through mammalian chromatin. Molecular Cell 19, 381-91 (2005).

Hong W, Nakazawa M, Chen YY, Kori R, Vakoc CR, Rakowski C, Blobel GA. FOG-1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA-1. EMBO Journal 24, 2367-78 (2005).

Vakoc CR, Letting DL, Gheldof N, Sawado T, Bender MA, Groudine M, Weiss MJ, Dekker J, Blobel GA. Proximity among distant regulatory elements at the beta-globin locus requires GATA-1 and FOG-1. Molecular Cell 17, 453-62 (2005)

Welch JJ, Watts JA, Vakoc CR, Yao Y, Wang H, Hardison RC, Blobel GA, Chodosh LA, Weiss MJ. Global regulation of erythroid gene expression by transcription factor GATA-1. Blood 104, 3136-47 (2004).